FNAM — Evolutionary Genomics Share Price
Last trade - 00:00- $0.00m
- $9.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -92.61% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.11 | 0.12 | 0.01 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially valuable traits in crops for the agriculture industry. It has performed research on crops including rice, corn, soybeans, wheat, cotton, cowpeas, beans, tomatoes, and cassava. Its core technology is its patented Adapted Traits Platform (ATP), which is used to perform molecular evolution analysis to identify positively selected genes that may have an impact on traits of interest. Positively selected candidate genes must be further tested to validate their impact on the desired traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes and cotton.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- February 4th, 2009
- Public Since
- March 3rd, 2011
- No. of Shareholders
- 324
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 6,655,232
- Address
- 4220 Morningstar Drive, CASTLE ROCK, 80108
- Web
- https://www.evolgen.com/
- Phone
- +1 7209008666
- Auditors
- Plante & Moran PLLC
Upcoming Events for FNAM
Similar to FNAM
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 20:34 UTC, shares in Evolutionary Genomics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Evolutionary Genomics last closed at $0.00 and the price had moved by -99.96% over the past 365 days. In terms of relative price strength the Evolutionary Genomics share price has underperformed the S&P500 Index by -99.96% over the past year.
There is no consensus recommendation for this security.
Find out moreEvolutionary Genomics does not currently pay a dividend.
Evolutionary Genomics does not currently pay a dividend.
Evolutionary Genomics does not currently pay a dividend.
To buy shares in Evolutionary Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Evolutionary Genomics had a market capitalisation of $0.00m.
Here are the trading details for Evolutionary Genomics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: FNAM
Based on an overall assessment of its quality, value and momentum Evolutionary Genomics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evolutionary Genomics. Over the past six months, its share price has underperformed the S&P500 Index by -74.93%.
As of the last closing price of $0.00, shares in Evolutionary Genomics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Evolutionary Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Evolutionary Genomics' directors